Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PBOHB vs Pilocarpine and Brimonidine in Presbyopia
NCT05001243Phase 1Unknown
- Sponsor
- Optall Vision
- Start
- Aug 2021
- Primary completion
- Aug 2021
- Modality
- Polymer-based Nanoparticles, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of pilocarpine, brimonidine, oxymetazoline, hyaluronic acid and bromfenac sodium in presbyopia (3 arms), sponsored by Optall Vision. Primary endpoint: Number of eyes improving 3 lines or more near visual acuity at 1 hour. Status: unknown.
02
Drugs
pilocarpinebrimonidineoxymetazolinehyaluronic acidbromfenac sodium
03
Conditions
presbyopia
Beyond the preview
Go deeper on NCT05001243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05001243.